Drug Profile
Research programme: non-beta-lactam penicillin-binding protein inhibitors - VenatoRx Pharmaceuticals
Alternative Names: PBP-539; VNRX-PBPLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator VenatoRx Pharmaceuticals
- Class Small molecules
- Mechanism of Action Penicillin-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Acinetobacter infections
- No development reported Gonorrhoea; Gram-positive infections
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Gonorrhoea in USA (PO)
- 28 Sep 2020 No recent reports of development identified for research development in Gram-positive-infections in USA (PO)
- 28 Jul 2020 Early research in Acinetobacter infections in USA (unspecified route)